Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in patients with acute coronary syndrome (ACS), and is a powerful predictor of long-term mortality. Differences in the clinical utility and pathophysiological implication of NT-proBNP and conventional cardiac markers in patients with ST elevation (STE) vs non-STE (NSTE) ACS were investigated in the present study.
-type natriuretic peptide (BNP) is a cardiac neurohormone predominantly secreted by the ventricles in response to increased myocardial stretch or wall tension. [1] [2] [3] Pro-BNP is synthesized as a pro-hormone by cardiac myocytes, and undergoes enzymatic cleavage to produce N-terminal pro-BNP (NT-proBNP) and BNP. 4 It has been reported that the serum level of NT-proBNP is elevated in patients with left ventricular (LV) dysfunction and shows a close correlation with the BNP level. We recently reported that the absolute increment of NT-proBNP exceeds that of BNP, and that NT-proBNP would be a more discerning marker for the detection and evaluation of cardiac dysfunction than BNP. 5, 6 Furthermore, recent clinical trials have shown that NT-proBNP is elevated in patients with acute coronary syndrome (ACS), and is a powerful predictor of both short and long-term mortality. [7] [8] [9] [10] [11] [12] The pathophysiology of ACS involves disruption of vulnerable plaque and thrombus formation, which produces severe myocardial ischemia and downstream embolization in the coronary vascular bed, leading to subendocardial or transmural necrosis. [13] [14] [15] [16] The clinical spectrum of ACS consists of ST elevation (STE) myocardial infarction (MI) (STEMI) and non-STE (NSTE) MI (NSTEMI)/or unstable angina (UA), which are classified from the acute phase electrocardiography (ECG) changes and the development of myocardial necrosis. STEMI is caused by acute total coronary occlusion, 17, 18 whereas NSTEMI is associated with vulnerable plaque and subocclusive thrombosis. 19 Novel cardiac markers, such as troponin T (TnT), and creatine kinase (CK)-MB isozyme, detect the development of minor myocardial necrosis, and have emerged as powerful predictors of risk in patients with ACS. [20] [21] [22] [23] The present study investigated differences in the secretion of NT-proBNP and conventional cardiac markers in patients with STE-ACS vs NSTE-ACS.
(Tokyo, Japan) from April 1999 to September 1999 because of acute chest pain or dyspnea were eligible for the present study. The inclusion criteria were a diagnosis of ACS, defined as UA according to Braunwald's classification, 24, 25 or acute MI (AMI) according to the redefined ESC/ACC Committee criteria. 26 The exclusion criteria were patients who had cardiopulmonary resuscitation before admission, presence of overt pump failure (≥Killip class II) in order to focus on the effect of myocardial ischemia per se on the release kinetics of NT-pro-BNP, or a serum creatinine level >2.0 mg/dl. All patients underwent standard 12-lead ECG immediately after admission, and blood samples were taken for biochemical measurements. The patients were classified into STE and NSTE groups based on the ECG findings on admission.
As demographic data, the history of hypertension, hyperlipidemia, diabetes mellitus (DM), and previous MI were investigated on admission. Echocardiography was performed within 24 h of admission to assess LV function. Undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) during hospitalization was investigated in all patients.
Of the 165 patients, 62 were excluded because they had non-ACS etiology (pneumonia, chronic obstructive pulmonary disease, esophageal or gastric disorders, congestive heart failure, acute aortic dissection, or stable angina) and another 13 patients fulfilled one or more of the exclusion criteria, thus 90 patients were analyzed in the present study.
Diagnostic Criteria for STE-ACS and NSTE-ACS
Patients with ST segment elevation at the J point in 2 or more consecutive leads (with the cut-off point being >0.2 mV in leads V1, V2, or V3, and >0.1 mV in the other leads) were defined as having STE-ACS. Patients with bundle-branch block were included in this group. Patients with ST segment depression, T wave inversion, or no ECG abnormalities were defined as having NSTE-ACS.
Blood Sampling
After informed consent was obtained, blood was collected on admission by direct venipuncture of an antecubital vein while the patient was supine. Blood samples were collected into tubes containing EDTA and centrifuged within 30 min, after which plasma CK-MB was measured by an immuno-inhibition assay (NAC, Merck, Darmstadt, Germany), and cardiac TnT levels were measured by an electrochemiluminescence assay (Elecsys 2010, Roche Diagnostics, Germany). Simultaneously obtained plasma was stored at -80°C until analysis of NT-proBNP. Plasma levels of NTproBNP were measured by an electrochemiluminescence assay (Elecsys 2010) within 2 years of sample collection.
Echocardiography
Transthoracic 2-dimensional echocardiography was performed within 24 h of admission by an experienced cardiologist. The LV end-diastolic and end-systolic diameters were measured according to the guidelines of the American Society of Echocardiography. 27 The LV ejection fraction (LVEF) was calculated by the modified Simpson's method in all 38 STE-ACS patients and 12 of the 52 NSTE-ACS patients, and by the Teichholz's method in other NSTE-ACS patients with a homogeneous contraction pattern.
Statistical Analysis
The NSTE-ACS and STE-ACS groups were compared by the Mann-Whitney U test. The cardiac markers were expressed as medians with interquartile ranges, and other continuous variables were expressed as mean ± standard deviation. Differences of percentages were compared by the chi-square test. The cardiac marker and NT-proBNP levels on admission were grouped according to the time from onset of chest pain to presentation at hospital, after which the values were compared between NSTE-ACS and STE-ACS patients. Linear regression analysis was done and correlation coefficients were calculated to assess the relationships between NT-proBNP and CK-MB, TnT, or LVEF. Comparison of 2 regression lines, slopes and intercepts, was performed to reveal the difference in NT-proBNP and TnT elevations between NSTE-ACS and STE-ACS patients. A p-value less than 0.05 was considered statistically significant.
Results

Demographic Data
The profiles of the NSTE-ACS and STE-ACS groups are shown in Table 1 . The mean age was 63.3±10.7 years and 65 patients (72.2%) were men. Of the 90 patients, 52 (57.8%) had NSTE-ACS and 38 (42.2%) had STE-ACS. There were no differences in age, gender, hyperlipidemia, DM or previous MI between the 2 groups, but the prevalence of hypertension was significantly higher in NSTE-ACS patients compared with STE-ACS patients (p<0.01).
Seventy-one patients had a final diagnosis of AMI according to the redefined ESC/ACC criteria 25 and 19 patients had UA. In the NSTE-ACS group, 35 patients (67.3%) had AMI and 17 patients (32.7%) had UA. In the STE-ACS group, 36 patients (94.7%) had AMI and 2 patients (5.3%) had UA (Table 2 ). There was no significant difference in the LVEF between NSTE-ACS patients (57.7±11.2%) and STE-ACS patients (55.1±12.7%) because we excluded patients with pump failure (≥Killip class II) in the present study to focus on the effect of myocardial ischemia per se. 
Cardiac Markers Conventional Cardiac Markers (CK-MB, TnT)
The CK-MB levels on admission were significantly higher in the STE-ACS patients than the NSTE-ACS patients (median level 18. (Fig 1a) . Similarly, TnT levels on admission were also significantly higher in the STE-ACS patients compared with NSTE-ACS patients (0.499 ng/ml [0.07-2.89] vs 0.147 ng/ml [0.01-0.68], p= 0.0268) (Fig 1b) . When the time from onset to presentation was divided into 3-h intervals, the median CK-MB level The conventional cardiac markers tendeds to be higher in the STE-ACS patients compared with NSTE-ACS patients at any time; however this did not reach statistical significance (Figs 2a,b) .
NT-ProBNP Unlike the conventional cardiac markers, the NT-proBNP level on admission was significantly higher in the NSTE-ACS patients compared with STE-ACS pa- (Fig 2c) . When the values for each time period were compared, NT-proBNP levels were significantly higher in the NSTE-ACS patients within 3 h of onset (0-3 h: NSTE-ACS vs STE-ACS, p=0.0132), and showed a tendency to be higher in patients admitted between 3 to 6 h of onset (p=0.0587), whereas there were no significant differences between the 2 groups after this time.
Correlations Between NT-ProBNP and Conventional Markers or LVEF
When the relationships between NT-proBNP and conventional markers were examined in the NSTE-ACS group, no significant correlation was found between NT-proBNP and CK-MB, but a significant positive correlation was observed between NT-proBNP and TnT (r=0.363, p=0.008) (Table 3) . Similarly, there was no correlation between NTproBNP and CK-MB levels in the STE-ACS group, but a significant positive correlation was observed between NTproBNP and TnT (r=0.474, p=0.003). When both groups were combined, a significant correlation was observed between NT-proBNP and TnT (r=0.273, p=0.010). There was no significant correlation between NT-proBNP and the LVEF obtained at acute-phase echocardiography in either the NSTE-ACS or STE-ACS groups.
When the correlation between NT-proBNP and TnT was analysed (Fig 3) , values for NSTE-ACS patients were distributed in the upper left region (y =717x + 837; r 2 =0.340), whereas the values for STE-ACS patients were clustered in the lower right region (y =253x + 247; r 2 =0.225). Comparison of the 2 regression lines revealed statistically significant difference in the slopes (t=2.846, p<0.001). The intercepts did not show significant difference. Thus, there was a remarkable difference in the elevations in the cardiac markers, with a significantly augmented elevation of NTproBNP (p<0.001) in NSTE-ACS patients compared with a prominent elevation of TnT in the STE-ACS patients.
Discussion
Differences Between NSTE-ACS and STE-ACS Patients
In the present study, CK-MB and TnT levels were higher in STE-ACS patients than in NSTE-ACS patients, whereas NT-proBNP was significantly higher during the early acute phase in the NSTE-ACS group than in the STE-ACS group. CK-MB is a marker of cytosolic damage that reflects the area at risk and the resultant size of the infarction, 28 whereas TnT is a marker of myofibril damage and is elevated in proportion to infarct size per se. 29, 30 Thus, the STE-ACS group with transmural infarction had a larger infarct size than the NSTE-ACS group. In contrast, NT-proBNP was higher in NSTE-ACS patients than in STE-ACS patients despite lower values of the conventional cardiac markers. We excluded patients with pump failure greater than Killip class II, which suggests that factors other than infarct size or pump failure had a fundamental influence on the elevation of NT-proBNP. In NSTE-ACS patients, the NT-proBNP values were significantly higher than would be expected from the TnT levels in the STE-ACS patients; NT-proBNP levels were clustered in the upper left region of the graph, unlike the TnT levels (Fig 3) . The 2 regression lines revealed a marked difference in the elevations, with a significantly augmented elevation of NT-proBNP (p<0.001) in NSTE-ACS patients as compared with prominent elevation of TnT in STE-ACS patients, again indicating the possibility that factors other than infarct size were more influential in NTSE-ACS patients.
Ischemic Insult and NT-ProBNP Elevation
The analyses according to the time-windows clarified this finding more obviously; that is, in NSTE-ACS patients the NT-proBNP level was significantly higher (almost 20-fold higher) than in the STE-ACS patients within 3 h of onset, and showed a tendency to be higher between 3 to 6 h of onset. Although the present study did not analyze sequential changes in the markers in each patient, these findings suggest the possibility of there being a larger ischemic insult in the earlier phase in NSTE-ACS patients regardless of the degree of myocardial necrosis, compared with that in STE-ACS patients.
Galvani et al reported similar findings in their multicenter study of patients with ACS. 31 The elevation of NT-proBNP was much higher in the NSTE-ACS patients than in the STE-ACS patients (506 pg/ml vs 201 pg/ml) in their study as well. Interestingly those values are almost consistent with our data: 758 pg/ml vs 258 pg/ml, respectively. Such early increases would reflect the amount of ischemic insult to the myocardium rather than the actual extent of myocardial damage or degree of heart failure. 32, 33 Thus, myocardial ischemia per se could be another mechanism leading to elevation of NT-proBNP, besides the presence of ventricular dysfunction. It could be also possible that early NTproBNP elevation in NSTE-ACS patients may reflect the consequences of repeated episodes of myocardial ischemia, both symptomatic and asymptomatic, occurring in the past several hours or days.
Goetze et al 34 analyzed the effect of acute myocardial hypoxia on cardiac BNP gene expression and peptide release using a porcine model with low oxygen delivery to the LV myocardium. They found a robust increase in the BNP mRNA content and an augmented increase in the immature BNP pre-mRNA content in the hypoxic myocardium after 2 h of hypoxia. Furthermore, they confirmed the increase in premature BNP mRNA in freshly harvested ventricular myocytes kept in oxygen-deprived culture flasks, and accumulation of proBNP peptide in the culture medium. Their study results strongly suggest that acute myocardial hypoxia/ischemia per se stimulates BNP expression and release of newly synthesized proBNP peptide.
In the present study, NT-proBNP levels were markedly elevated in ACS patients, especially in the NSTE-ACS group. Taken together with the previous results, NTproBNP could be an early sensitive marker of myocardial ischemia that rises much higher than be expected than the TnT levels in NSTE-ACS patients, and even in the absence of heart failure.
Relationship Between Cardiac Function and TnT or NT-ProBNP
We previously reported a significant correlation between the TnT level and the wall motion score during the acute phase of AMI 35 and a correlation between the TnT level and LVEF was also found in the present study (R =-0.268, p=0.02). However, there was no correlation between NTproBNP and LVEF. In patients with heart failure, we have reported that NT-proBNP and BNP show a progressive increase in proportion to the New York Heart Association (NYHA) classification, and that there is a significant correlation between NT-proBNP and BNP. In particular, NTproBNP was elevated even when the decrease of LVEF was minor (LVEF >50%), so it is a more discerning marker for detecting heart failure than BNP. 6 However, the present study found no correlation between the level of NTproBNP and LVEF in ACS patients. In our previous study, the mean value of NT-proBNP in NYHA class I patients was 103.4 pg/ml and it rose to 622.2 pg/ml in class II patients. 6 The mean value in patients with dilated cardiomyopathy was 533.7 pg/ml and that for valvular heart disease was 837.2 pg/ml, but NT-proBNP always remained below 1,000 pg/ml. In contrast, the present study showed that NTproBNP levels in patients with ACS were extremely high; in particular, a mean value of 1,573 pg/ml for the NSTE-ACS group, even though cardiac function was maintained (LVEF 57.7±11.2%). These findings suggest that elevation of NT-proBNP in ACS patients does not necessary reflect heart failure, but rather is a result of myocardial ischemia itself.
Clinical Implications and Study Limitations
The present study demonstrated that NT-proBNP is significantly higher during the hyper acute phase in NSTE-ACS patients, and is not raised by the process of myocardial necrosis but by the ischemic insult per se. Our results suggest that the release kinetics of cardiac markers, especially NT-proBNP, in patients with NSTE-ACS differ from those in STE-ACS patients. It is conceivable that the ischemic area or the area at risk show a different spectrum in these 2 groups. To elucidate the difference, comparison by radioisotope or positron emission tomography assessment during the acute phase would be necessary. As another possibility, it must be taken into consideration that patients with pump failure (≥Killip class II) were excluded from the present study, and analysis was confined to uncomplicated ACS (Killip class I). Thus, the present study did not assess the dynamic changes of NT-proBNP synthesis/secretion during the process from the onset of ischemia to the development of pump failure. Further studies are needed to elucidate the possible differences in the prognostic implication of NTproBNP between NSTE-ACS and STE-ACS patients.
